BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 11430933)

  • 1. In vitro effects of E3040, a dual inhibitor of 5-lipoxygenase and thromboxane A(2) synthetase, on eicosanoid production.
    Oketani K; Nagakura N; Harada K; Inoue T
    Eur J Pharmacol; 2001 Jun; 422(1-3):209-16. PubMed ID: 11430933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of E3040, an inhibitor of 5-lipoxygenase and thromboxane synthase, on rat bowel damage induced by lipopolysaccharide.
    Oketani K; Inoue T; Murakami M
    Eur J Pharmacol; 2001 Sep; 427(2):159-66. PubMed ID: 11557269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel dual inhibitors of 5-lipoxygenase and thromboxane A2 synthetase: synthesis and structure-activity relationships of 3-pyridylmethyl-substituted 2-amino-6-hydroxybenzothiazole derivatives.
    Hibi S; Okamoto Y; Tagami K; Numata H; Kobayashi N; Shinoda M; Kawahara T; Murakami M; Oketani K; Inoue T
    J Med Chem; 1994 Sep; 37(19):3062-70. PubMed ID: 7932529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E3040 sulphate, a novel thromboxane synthase inhibitor, blocks the Cl- secretion induced by platelet-activating factor in isolated rat colon.
    Sakai H; Suzuki T; Murota M; Oketani K; Uchiumi T; Murakami M; Takeguchi N
    Br J Pharmacol; 2002 Jun; 136(3):383-90. PubMed ID: 12023941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of a novel dual inhibitor of thromboxane A2 synthetase and 5-lipoxygenase (E3040) via the direct coupling reaction of hydroquinone with 3-pyridinecarboxaldehyde.
    Komatsu Y; Minami N
    Chem Pharm Bull (Tokyo); 1995 Oct; 43(10):1614-6. PubMed ID: 8536337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase.
    Hibi S; Okamoto Y; Tagami K; Numata H; Kobayashi N; Shinoda M; Kawahara T; Harada K; Miyamoto K; Yamatsu I
    J Med Chem; 1996 Aug; 39(16):3148-57. PubMed ID: 8759636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of platelet thromboxane synthetase by sulfasalazine.
    Stenson WF; Lobos E
    Biochem Pharmacol; 1983 Jul; 32(14):2205-9. PubMed ID: 6135423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WY-50,295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity.
    Grimes D; Sturm RJ; Marinari LR; Carlson RP; Berkenkopf JW; Musser JH; Kreft AF; Weichman BM
    Eur J Pharmacol; 1993 May; 236(2):217-28. PubMed ID: 8391458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor.
    Li L; Ji H; Sheng L; Zhang Y; Lai Y; Chen X
    Eur J Pharmacol; 2009 Apr; 607(1-3):244-50. PubMed ID: 19243697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of sulfasalazine and a sulfasalazine analogue on the formation of lipoxygenase and cyclooxygenase products.
    Tornhamre S; Edenius C; Smedegård G; Sjöquist B; Lindgren JA
    Eur J Pharmacol; 1989 Oct; 169(2-3):225-34. PubMed ID: 2572437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of acetylshikonin, a natural naphthoquinone, on the production of leukotriene B4 and thromboxane A2 in rat neutrophils.
    Hsu MF; Chang LC; Huang LJ; Kuo SC; Lee HY; Lu MC; Wang JP
    Eur J Pharmacol; 2009 Apr; 607(1-3):234-43. PubMed ID: 19232341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological studies on the TXA2 synthetase inhibitor (E)-3-[p-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid (OKY-046).
    Hiraku S; Taniguchi K; Wakitani K; Omawari N; Kira H; Miyamoto T; Okegawa T; Kawasaki A; Ujiie A
    Jpn J Pharmacol; 1986 Jul; 41(3):393-401. PubMed ID: 3093741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of the uricosuric action of the anti-inflammatory drug E3040 used to treat inflammatory bowel disease I: study using a rat model of hyperuricemia.
    Yamada H; Kotaki H; Furitsu H; Sawada Y; Iga T
    Biopharm Drug Dispos; 1999 Mar; 20(2):77-83. PubMed ID: 10206322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models.
    Carty TJ; Sweeney FJ; Griffiths RJ; Eskra JD; Ernest MJ; Pillar JS; Cheng JD; Loose LD; Joseph PA; Pazoles PP; Moore PF; Nagahisa A; Murase S; Kadin SB
    Inflamm Res; 1997 May; 46(5):168-79. PubMed ID: 9197987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
    Argentieri DC; Ritchie DM; Ferro MP; Kirchner T; Wachter MP; Anderson DW; Rosenthale ME; Capetola RJ
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1399-408. PubMed ID: 7996452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different biliary excretion systems for glucuronide and sulfate of a model compound; study using Eisai hyperbilirubinemic rats.
    Takenaka O; Horie T; Suzuki H; Sugiyama Y
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1362-9. PubMed ID: 7562509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential inhibition of thromboxane B2 and leukotriene B4 biosynthesis by two naturally occurring acetylenic fatty acids.
    Croft KD; Beilin LJ; Ford GL
    Biochim Biophys Acta; 1987 Oct; 921(3):621-4. PubMed ID: 2822134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carrier-mediated active transport of the glucuronide and sulfate of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) into rat liver: quantitative comparison of permeability in isolated hepatocytes, perfused liver and liver in vivo.
    Takenaka O; Horie T; Suzuki H; Sugiyama Y
    J Pharmacol Exp Ther; 1997 Feb; 280(2):948-58. PubMed ID: 9023311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-performance liquid chromatographic quantitation of cyclooxygenase and lipoxygenase metabolites of arachidonic acid from rat polymorphonuclear leukocytes.
    Tordjman C; Serkiz B; Rambaud F; Bonnet J; Volland JP
    J Chromatogr; 1990 Oct; 532(1):135-43. PubMed ID: 1964162
    [No Abstract]   [Full Text] [Related]  

  • 20. Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
    McMillan RM; Spruce KE; Crawley GC; Walker ER; Foster SJ
    Br J Pharmacol; 1992 Dec; 107(4):1042-7. PubMed ID: 1334748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.